Panel requires stricter safety criteria for blood system trial

11/17/2009 | Forbes

The FDA's Blood Products Advisory Committee has required Cerus to tighten safety parameters for a late-stage study involving its intercept blood system, which inhibits blood-borne pathogens in blood components used for transfusions. The company said it may take a year to finish preparations for the planned trial.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC